DataMeds AI plans ChemoFx marketing relaunch, targets gynecologic cancer diagnostic rollout
DataMeds AI will cut corporate management roles to redirect spending toward commercializing the ChemoFx diagnostic for gynecologic cancers. A marketing relaunch is being prepared, targeting oncologists to drive adoption of ChemoFx for chemotherapy regimen selection. ChemoFx will be positioned for broader payer uptake f